---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-23-000011"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:08:50.190617+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Rallybio reports Q3 2023 net loss of $18.4M ($0.45/share); cash $121.4M, runway into Q1 2025

## Summary
- Net loss of $18.4M, or $0.45 per share, unchanged from Q3 2022 net loss of $18.4M ($0.60 per share).
- R&D expenses $13.3M (up vs $12.1M in Q3 2022) on advancing RLYB212 and RLYB331; G&A expenses $6.1M (down from $6.8M).
- Cash, cash equivalents and marketable securities $121.4M as of Sept 30, 2023; expected to fund operations into Q1 2025.
- On track for 4Q 2023 data readouts: RLYB212 Phase 1 multiple dose cohort initial data and RLYB116 Phase 1 MAD data including safety, PK, PD.
- RLYB212 Phase 2 dose confirmation study in pregnant women expected to initiate in H2 2024.

## SEC filing metadata
- accession: 0001739410-23-000011
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941023000011/0001739410-23-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941023000011/rlyb-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-23-000011
- JSON: https://secwatch.observer/filing/0001739410-23-000011.json
- Plain text: https://secwatch.observer/filing/0001739410-23-000011.txt

## Key facts
- Earnings Releases
  Rallybio Corp reported the third quarter ended September 30, 2023 results: net income Net loss was $18.4 million for the third quarter of 2023, or net loss per common share of $0.45, EPS net loss per common share of $0.45.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net loss was $18.4 million for the third quarter of 2023, or net loss per common share of $0.45
  - EPS: net loss per common share of $0.45
  - Result: reported results
  source text: Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000173941023000011/0001739410-23-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.